Population versus individual protection by pneumococcal conjugate vaccination

doi:10.1016/S0140-6736(19)30039-X

Comment

. 2019 May 25;393(10186):2102-2104.

doi: 10.1016/S0140-6736(19)30039-X. Epub 2019 Apr 15.

Population versus individual protection by pneumococcal conjugate vaccination

Keith P Klugman¹, Gail L Rodgers²

Affiliations

¹ Bill & Melinda Gates Foundation, Seattle, WA 98119, USA. Electronic address: keith.klugman@gatesfoundation.org.
² Bill & Melinda Gates Foundation, Seattle, WA 98119, USA.

PMID: 31000193
PMCID: PMC7771528
DOI: 10.1016/S0140-6736(19)30039-X

Comment

Population versus individual protection by pneumococcal conjugate vaccination

Keith P Klugman et al. Lancet. 2019.

. 2019 May 25;393(10186):2102-2104.

doi: 10.1016/S0140-6736(19)30039-X. Epub 2019 Apr 15.

Authors

Keith P Klugman¹, Gail L Rodgers²

Affiliations

¹ Bill & Melinda Gates Foundation, Seattle, WA 98119, USA. Electronic address: keith.klugman@gatesfoundation.org.
² Bill & Melinda Gates Foundation, Seattle, WA 98119, USA.

PMID: 31000193
PMCID: PMC7771528
DOI: 10.1016/S0140-6736(19)30039-X

No abstract available

PubMed Disclaimer

Figures

None — James Cavallini/Science Photo Library

See this image and copyright information in PMC

Comment on

Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG. Hammitt LL, et al. Lancet. 2019 May 25;393(10186):2146-2154. doi: 10.1016/S0140-6736(18)33005-8. Epub 2019 Apr 15. Lancet. 2019. PMID: 31000194 Free PMC article.

Cited by

Estimating the contribution of HIV-infected adults to household pneumococcal transmission in South Africa, 2016-2018: A hidden Markov modelling study.
Thindwa D, Wolter N, Pinsent A, Carrim M, Ojal J, Tempia S, Moyes J, McMorrow M, Kleynhans J, Gottberg AV, French N; PHIRST group; Cohen C, Flasche S. Thindwa D, et al. PLoS Comput Biol. 2021 Dec 23;17(12):e1009680. doi: 10.1371/journal.pcbi.1009680. eCollection 2021 Dec. PLoS Comput Biol. 2021. PMID: 34941865 Free PMC article.
Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials.
Bollaerts K, Fletcher MA, Suaya JA, Hanquet G, Baay M, Gessner BD. Bollaerts K, et al. Clin Infect Dis. 2022 Apr 28;74(8):1362-1371. doi: 10.1093/cid/ciab649. Clin Infect Dis. 2022. PMID: 34313721 Free PMC article.
Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa.
Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S. Thindwa D, et al. Expert Rev Vaccines. 2020 Nov;19(11):1085-1092. doi: 10.1080/14760584.2020.1843435. Epub 2020 Dec 3. Expert Rev Vaccines. 2020. PMID: 33269987 Free PMC article. Review.
Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017.
Soeters HM, Kambiré D, Sawadogo G, Ouédraogo-Traoré R, Bicaba B, Medah I, Sangaré L, Ouédraogo AS, Ouangraoua S, Yaméogo I, Congo-Ouédraogo M, Ky Ba A, Aké F, Srinivasan V, Novak RT, McGee L, Whitney CG, Van Beneden C. Soeters HM, et al. J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S253-S262. doi: 10.1093/infdis/jiz301. J Infect Dis. 2019. PMID: 31671444 Free PMC article.

References

1. Hammitt LL, Etyang AO, Morpeth SC, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019; published online April 15 10.1016/S0140-6736(18)33005-8 - DOI - PMC - PubMed
1. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15: 301–09. - PMC - PubMed
1. von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371: 1889–99. - PubMed
1. Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association between the decline in pneumococcal disease in unimmunized adults and vaccine-derived protection against colonization in toddlers and preschool-aged children. Am J Epidemiol 2018; 188: 160–68. - PMC - PubMed
1. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J 2014; 35: 504–10. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Hammitt LL, Etyang AO, Morpeth SC, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019; published online April 15 10.1016/S0140-6736(18)33005-8 - DOI - PMC - PubMed

[2] Hammitt LL, Etyang AO, Morpeth SC, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019; published online April 15 10.1016/S0140-6736(18)33005-8 - DOI - PMC - PubMed

[3] Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15: 301–09. - PMC - PubMed

[4] Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15: 301–09. - PMC - PubMed

[5] von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371: 1889–99. - PubMed

[6] von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371: 1889–99. - PubMed

[7] Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association between the decline in pneumococcal disease in unimmunized adults and vaccine-derived protection against colonization in toddlers and preschool-aged children. Am J Epidemiol 2018; 188: 160–68. - PMC - PubMed

[8] Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association between the decline in pneumococcal disease in unimmunized adults and vaccine-derived protection against colonization in toddlers and preschool-aged children. Am J Epidemiol 2018; 188: 160–68. - PMC - PubMed

[9] Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J 2014; 35: 504–10. - PubMed

[10] Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J 2014; 35: 504–10. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Population versus individual protection by pneumococcal conjugate vaccination

Affiliations

Population versus individual protection by pneumococcal conjugate vaccination

Authors

Affiliations

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical